DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for juxtacortical osteosarcoma — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleJuxtacortical osteosarcoma maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for juxtacortical osteosarcoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
GNAS complex locus (GNAS) — GNAS is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet oladrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8WW2 · 2.79 Å · ligand OLEIC ACID (OLA). Experimental structure, not a prediction.
What the evidence adds up to
Juxtacortical osteosarcoma is a rare malignant mesenchymal tumour, accounting for less than 4% of all osteosarcomas and 1% of all bone tumours, with an incidence of 0.07 per 100,000 population. It includes intermediate-grade periosteal and low-grade paraosteal variants, which have less aggressive biological behaviour than conventional central medullary osteosarcoma. A total of eighty cases were studied across a literature review and the archives of the Netherlands Committee on Bone Tumors, leading to the conclusion that juxtacortical osteosarcoma should be considered a distinctive entity. The tumour can cause diagnostic dilemma and be confused with peripheral fibro-osseous lesions.
One case report describes a 43-year-old female with juxtacortical osteosarcoma of the mandible. The success rate of treatment is reported as good if the tumour is detected early and resected with wide margins, giving a negligible chance for recurrence. Juxtacortical osteosarcoma of the jaws appears to have a slightly more favourable prognosis than in long bones, though the authors note that a larger series of cases needs to be evaluated before a definitive conclusion can be made.
No abstract in this set reports any drug treatment, response rates, or survival numbers for juxtacortical osteosarcoma. The evidence is limited to case series and single case reports, with no controlled trials or comparative data on medical therapy.
What is still missing is any prospective trial design, any data on systemic therapy or drug repurposing, and any patient stratification beyond the anatomical site distinction between jaw and long bones. Funding for a larger, multi-centre series would be needed to establish whether the apparent prognostic difference between jaw and long bone tumours is real.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Bone and Joint Surgery · 1967 · 86 citations
Juxtacortical Osteosarcoma
AbstractTo study the relation of juxtacortical osteosarcoma to intraosseous osteosarcoma and to re-evaluate the treatment of the former, sixty-four cases were collected from the literature and sixteen cases from the archives of the Netherlands Committee on Bone Tumors. A total of eighty cases were studied. It is concluded that juxtacortical osteosarcoma should be considered a distinctive entity, and a scheme for treatment based on its distinctive features is proposed.
Annals of Maxillofacial Surgery · 2011 · 8 citations · open access
Juxtacortical osteosarcoma of mandible
AbstractThis article presents a case of juxtacortical (paraosteal) osteosarcoma in a 43-year-old female, which is rare malignant mesenchymal tumor. As per the literature, it accounts for less than 4% of all osteosarcomas. Due to its rare variety, this tumor can cause diagnostic dilemma and clinicians should be aware of it. Due to its clinical picture, it can be confused with peripheral fibro-osseous lesions. Success rate of treatment are good if the tumor is detected early and resected with wide margins giving a negligible chance for recurrence.
The Internet Journal of Ophthalmology and Visual Science · 2010 · 1 citations · open access
A Non Responding Case Of Extraocular Muscle Cysticercosis Mimicking As Pseudo-Tumor Orbit In A Child
AbstractOsteosarcoma is the true malignant neoplasm of bone in which the malignant osteoblasts differentiate from the sarcomatous stroma and produce tumorous osteoid, tumorous bone and sometimes even tumorous cartilage. An uncommon separate class of osteosarcomas termed juxtacortical osteosarcoma, which includes intermediate grade periosteal and low-grade paraosteal variants represents less than 4% of all osteosarcomas and 1 % of all bone tumours. Juxtacortical osteosarcoma (incidence of 0.07 per 100,000 populations) occurs much less commonly than central medullary osteosarcoma. They have less aggressive biological behaviour as compared to the conventional type. So it is important to recognize these subtypes of osteosarcomas to plan treatment appropriately and avoid overtreatment. Juxtacortical osteosarcoma of the jaws appears to have a slightly more favourable prognosis than in long bones, although a larger series of cases needs to be evaluated before a definitive conclusion concerning the behaviour of juxtacortical osteosarcoma of the jaws can be made.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
